Filing Details
- Accession Number:
- 0001209191-20-047504
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-08-19 16:35:46
- Reporting Period:
- 2020-08-17
- Accepted Time:
- 2020-08-19 16:35:46
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1556263 | Syros Pharmaceuticals Inc. | SYRS | Pharmaceutical Preparations (2834) | 453772460 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1678149 | R Eric Olson | C/O Syros Pharmaceuticals, Inc. 35 Cambridgepark Drive Cambridge MA 02140 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-08-17 | 4,963 | $1.01 | 4,963 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-08-17 | 4,963 | $13.00 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2020-08-18 | 10,787 | $1.01 | 10,787 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-08-18 | 10,787 | $13.00 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2020-08-17 | 4,963 | $0.00 | 4,963 | $1.01 |
| Common Stock | Stock Option (right to buy) | Disposition | 2020-08-18 | 10,787 | $0.00 | 10,787 | $1.01 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 105,112 | 2023-05-22 | No | 4 | M | Direct | |
| 94,325 | 2023-05-22 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- This option is fully vested.
Billionaire Hedge Funds
